Showing results (181-190 of 451) with videos related to
Sort By:
Pageof 46
Rheumatology (Oxford, England)|August 22, 2012
Gut fibrosis with altered colonic contractility in a mouse model of sclerodermaNora M Thoua, Emma C Derrett-Smith, Korsa Khan, et al.Arthritis Research & Therapy|October 1, 2025
The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosisCamilla Sa Davan-Wetton, Natalya Khodeneva, Christopher P Denton, et al.Arthritis and Rheumatism|May 29, 2007
Normal circulating serum amyloid P component concentration in systemic sclerosisGlenys A Tennent, Magdalena Dziadzio, Eva Triantafillidou, et al.Journal of Scleroderma and Related Disorders|April 6, 2022
Cardiac transplantation in a 20-year-old woman with sclerodermaBenjamin E Schreiber, Victoria Parish, Daniel S Knight, et al.The European Respiratory Journal|August 29, 2024
Definition, classification and diagnosis of pulmonary hypertensionGabor Kovacs, Sonja Bartolome, Christopher P Denton, et al.Annals of the Rheumatic Diseases|January 17, 2012
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO RegistryChristopher P Denton, Thomas Krieg, Loic Guillevin, et al.Arthritis and Rheumatism|April 1, 2006
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblastsYunliang Chen, Xu Shi-wen, Mark Eastwood, et al.Annals of the Rheumatic Diseases|July 30, 2026
Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trialShervin Assassi, Masataka Kuwana, Christopher P Denton, et al.The Journal of Rheumatology|April 3, 2008
Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosisMaria Teresa Carulli, Paolo Spagnolo, Carmen Fonseca, et al.Annals of the Rheumatic Diseases|September 23, 2020
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosisYannick Allanore, Peter Wung, Christina Soubrane, et al.Pageof 46